A Look Back at Cell and Gene Therapy Progress in 2022
Despite considerable headwinds confronting the entire biopharmaceutical industry, 2022 has been a banner year for approvals in the cell and gene therapy space. While investment in the sector is not yet back to where it was two years ago, the industry is once again trending up when it comes to research and development spending and forging partnerships. The success of innovative products launched over the next few years will likely depend on the ability of companies both to gain access to new markets and implement value-based pricing arrangements. However, meeting program timelines and delivering on commitments to the investment community will also be critical for firms to achieve any future commercial success and to maintain momentum in the space.
We invite you to read our perspective on the Cell & Gene Therapy space in 2022.